Work

1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1331

Authors: S.J. Klempner, J. Chao, H. Uronis, C. Sirard, M. Kagey, J. Baum, J. Song, J. Wang, M.B. Sonbol, Z.A. Wainberg, J.A. Ajani

Institutions: Massachusetts General Hospital, City Of Hope National Medical Center, City of Hope, Duke Medical Center, Leap Therapeutics, Inc. (United States), BeiGene (China), Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Arizona), University of California, Los Angeles, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Japan Agency for Medical Research and Development, Chugai Pharmaceutical

OpenAlex ID: W4295828467

FWCI: 0.484

Cites: 1

Cited by: 3

Related to: 10